deutenomics, stable isotope biology, deuterium, deutenome, isotopic control of cellular energy production, mitochondrial inclusion zone water, deupletion, 2H
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.
For physicians and scientists interpreting these observations, it would be highly informative to situate them within the documented conceptual and translational limitations of chemically modified mRNA drug design. These limitations have been articulated in peer-reviewed medical biochemistry literature:
1) Early identification of design constraints (Science Advances, first published 26 June 2021; https://t.co/X8LvwFhsr2). This work, along with its associated eLetters, highlighted fundamental issues arising from high-stoichiometry nucleoside modifications.
2) Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1218 (first published 12 June 2024; https://t.co/JVqb8ACLlB). This review documents prolonged persistence of modified mRNA and the generation of frameshifted spike-protein products in human tissues and circulation.
3) Conceptual and translational pitfalls of modified messenger RNA drug design with public health impact. Hum Genomics. 2026 (first published 16 October 2026; https://t.co/RMxI6FKYjb). This analysis details non-physiological levels of N1-methylpseudouridine (approximately 50 % of bases versus the 0.2–0.6 % Ψ/U ratio typical of endogenous eukaryotic mRNA), disruption of normal mRNA turnover, impaired innate immune sensing, potential reverse transcription, ribosomal frameshifting, and uncontrolled antigen production.
Collectively, these studies demonstrate that the core chemical strategy—uniform or near-uniform substitution of uridine with N1-methylpseudouridine to evade TLR recognition and extend mRNA half-life—introduces intrinsic uncertainties in translation fidelity, protein identity, and pharmacological duration. Incorporating this established biochemical context would help readers understand why certain toxicities may not be purely idiosyncratic but can stem from platform-level design features, thereby reducing reliance on post-hoc speculation.